Iron Chelation Enhances TAM and Triple-Negative Breast Cancer Cell Death

Abstract

The goal of this study is preclinical testing of Deferiprone (DFP), an iron chelator in clinical use for non-oncologic diseases. We completed in vitro testing proposed in the application. We found that DFP increased M1 polarization(even in the absence of IL4 or LPS) and also in the presence of LPS. DFP enhanced the efficiency of phagocytosis by RAW264.7 cells and was significant in all the culture conditions (p = 0.0004 for Control, p = 0.0007 for IL-4, p = 0.0045 for LPS) but most prominent in the LPS treated group. We measured the tumor cell doubling times including an additional cell line (BT474) and the effect of DFP and found the results similar in all 3 breast cancer cell lines. The IC50 values for the BT474 were similar to the 4T1 and MBA-231 cells.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2021
Accession Number
AD1164115

Entities

People

  • Jason A Koutcher

Organizations

  • Memorial Sloan Kettering Cancer Center

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Anti-Bacterial Agents
  • Azo Compounds
  • Biomedical Research
  • Breast Cancer
  • Cancer
  • Cells
  • Chemistry
  • Culture Techniques
  • Lymphocytes
  • Medical Personnel
  • Metabolism
  • Neoplasms
  • Prostate Cancer
  • Proteins
  • Rate Of Consumption
  • Standards
  • Statistical Analysis

Fields of Study

  • Medicine

Readers

  • Aerospace Engineering
  • Microbial Pathology
  • Oncology (Cancer Research).